Entering text into the input field will update the search result below

OncoMed Pharmaceuticals' (OMED) CEO Sunil Patel on Q3 2017 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

OncoMed Pharmaceuticals Inc (NASDAQ:OMED-OLD) Q3 2017 Earnings Conference Call November 2, 2017 4:30 PM ET


Peter Rahmer - Managing Director, Trout Group

Sunil Patel - Executive Vice President and Chief Financial Officer

John Lewicki - Executive Vice President of Research and Development

Robert Stagg - Senior Vice President of Clinical Research and Development


Maury Raycroft - Jefferies

Michael Schmidt - Leerink

Mike King - JMP Securities

Nick Abbott - Wells Fargo

Peter Lawson - SunTrust Robinson


Good afternoon, everyone, and welcome to the OncoMed Pharmaceuticals 2017 Third Quarter Financial Results Conference Call. This call is being recorded.

At this time, for opening remarks and introductions, I would like to turn the call over to Mr. Peter Rahmer, Managing Director at Trout Group.

Peter Rahmer

Thank you, Amanda. Hello, everyone, and welcome to OncoMed Pharmaceuticals financial results and corporate update call for the third quarter of 2017.

Leading the call today is Sunil Patel, our Executive Vice President and Chief Financial Officer. He is joined by John Lewicki, our Executive Vice President of Research and Development; Bob Stagg, our Senior Vice President of Clinical Research and Development; and Perry Karsen, Director and Member of the Special Committee of the Board.

Before we get started, I'd like to remind you that during this conference call, OncoMed will make certain statements that are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our business plans and objectives, and timing and success of our clinical trials. Such forward-looking statements are not guarantees of future performance and therefore you should not put undue reliance upon them. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. I refer you to our SEC filings for a discussion of risk factors that could

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.